Market growth will be propelled by wider acceptance of neuromodulation products, allowing them to be used on a larger proportion of potential patients. In addition, many neuromodulation patients require multiple devices over their lifetimes because the battery life of neuromodulation devices are limited, ranging from three to ten years. Furthermore, the neuromodulation market had a relatively low penetration rate in 2016 and therefore has excellent growth potential. The GES market will be the slowest growing segment in the neuromodulation device market because the procedure has not gained widespread acceptance and the device only has humanitarian device exemption (HDE) status, limiting its usage to 4,000 units per year. The fastest growing segment is projected to be the DBS market. This market will benefit from the expected entry of new competitors into the market, which will lead to increasing ASP and unit sales through the established sales network of St. Jude Medical and potentially Boston Scientific.